GLP-1s Are Changing Bodies Faster Than Surgery Can Keep Up

More than 12% of American adults are now taking a GLP-1 medication — a number that more than doubled in the past eighteen months alone. These drugs are genuinely, historically remarkable. Semaglutide produces roughly 15% total body weight loss in clinical trials. Tirzepatide pushes that to nearly 21%. For millions of people who have struggled with obesity for decades, that is life-changing. The cardiovascular benefits, the metabolic reset, the relief from joint pain, the restored energy — this is real medicine doing real things.But there is a downstream consequence that the prescribing community — primary care, endocrinology, obesity medicine — is not consistently preparing patients for. When you lose 50, 60, 80 pounds in under a year, your skin doesn't know what happened. Your face doesn't know what happened. Your breasts don't know. And the aesthetic consequences — Ozempic face, skin laxity, deflated body contours, muscle loss — are landing patients in plastic surgery consult rooms faster than the field can adapt.In this episode, Dr. Chris Lee and Jenna Gomez take a firmly pro-GLP-1 stance while giving patients the full picture: what these drugs actually do, why the aesthetic side effects happen, what can be done about them, and — critically — what patients should be doing from day one to protect themselves.Episode Overview1: What GLP-1s actually do and why they work so well2: Ozempic face — the mechanism, the reality, and the fix3: The body: skin laxity, muscle loss, and breast deflation4: The surgical wave — what procedures are surging and why5: Chris's honest take — should you be on one?